根治性前列腺切除术后中度大分割放疗的安全性与疗效:II期试验
这项单臂II期研究评估了前列腺癌根治性切除术后辅助或挽救性中度大分割放疗(54 Gy/18次)的安全性和疗效,共55例患者接受治疗,中位随访37.3个月。3年生化无复发生存率为65.8%,≥2级急性泌尿生殖毒性和胃肠道毒性发生率分别为5.5%和34.5%,总体毒性可控,支持该方案的可行性。
要点
- 54 Gy/18次中度大分割放疗用于术后辅助或挽救治疗,3年bRFS为65.8%。
- ≥2级急性GU毒性5.5%,急性GI毒性34.5%,以2级为主。
- ≥2级晚期GU和GI毒性分别为14.6%和21.8%,生活质量基本维持。
核心结论
- 根治性前列腺切除术后54 Gy/18次中度大分割放疗获得较好的生化控制,毒性总体可控,支持其可行性。
研究设计与样本
- 单臂II期试验,纳入≥20岁行根治性前列腺切除术并计划辅助或挽救放疗、ECOG 0-2、无既往盆腔放疗或远处转移的男性患者。
- 放疗为容积旋转调强放疗至前列腺床,54 Gy/18次,可选盆腔淋巴结床照射;主要终点为≥2级急性泌尿生殖和胃肠道毒性发生率。
主要发现
- 挽救性放疗49例(89%),辅助放疗6例(11%);53%接受同期雄激素剥夺治疗。
- ≥2级急性GU和GI毒性发生率分别为5.5%和34.5%,GI事件以2级为主,1例(1.8%)发生3级小肠梗阻。
- ≥2级晚期GU和GI毒性发生率分别为14.6%和21.8%。
- 3年bRFS为65.8%(95%CI 51.1-77.1),生活质量基本维持,短暂肠道症状3个月内缓解。
关键数值与推荐
- 放疗剂量方案:54 Gy分18次,容积旋转调强放疗至前列腺床,可选盆腔淋巴结床照射。
- 主要终点≥2级急性GU毒性5.5%,急性GI毒性34.5%;≥2级晚期GU毒性14.6%,晚期GI毒性21.8%。
- 3年bRFS 65.8%(95%CI 51.1-77.1)。
临床怎么用
- 对于根治性前列腺切除术后需辅助或挽救放疗的患者,可考虑54 Gy/18次中度大分割方案。
- 治疗中需关注胃肠道毒性,尤其是急性GI事件,多数为2级但偶见3级。
- 该方案可行性得到支持,但需在更长随访中进一步验证晚期毒性和生化控制。
局限性
- 单臂II期设计,样本量55例,随访时间相对较短(中位37.3个月)。
- 缺乏随机对照,无法直接比较常规分割放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This single-arm phase II study evaluated the safety and efficacy of moderately hypofractionated radiotherapy (RT) after radical prostatectomy (RP) for prostate cancer in the adjuvant or salvage setting. MATERIALS AND METHODS: Eligible patients were men aged ≥ 20 years who had undergone RP and were scheduled for adjuvant or salvage RT, with an Eastern Cooperative Oncology Group performance status of 0-2 and no prior pelvic RT or distant metastasis. RT consisted of 54 Gy in 18 fractions delivered with volumetric modulated arc therapy to the prostate bed, with optional pelvic lymph nodal bed irradiation. The primary endpoint was the incidence of grade ≥ 2 acute genitourinary (GU) and gastrointestinal (GI) toxicity. Secondary endpoints included biochemical recurrence-free survival (bRFS), toxicity, and quality of life (QoL). RESULTS: Between December 2018 and November 2021, 55 patients received protocol treatment. The median follow-up was 37.3 months. Salvage RT was performed in 49 patients (89%) and adjuvant RT in six (11%); 53% received concurrent androgen deprivation therapy. Grade ≥ 2 acute GU and GI toxicities occurred in 5.5% and 34.5% of patients, respectively; GI events were predominantly grade 2, with one patient (1.8%) experiencing grade 3 small bowel obstruction. During the relatively short follow-up period (median, 37.3 months), grade ≥ 2 late GU and GI toxicities were observed in 14.6% and 21.8% of patients, respectively. The 3-year bRFS was 65.8% (95% confidence interval, 51.1-77.1). QoL was largely maintained, with transient bowel symptoms resolving within three months. CONCLUSION: Moderately hypofractionated RT of 54 Gy in 18 fractions after RP achieved favorable biochemical control with generally manageable toxicity, supporting its feasibility.
引用
- Sawayanagi S, Yamashita H, Kawai T, et al. Safety and efficacy of moderately hypofractionated radiotherapy after radical prostatectomy: A phase II trial. Radiother Oncol. 2026. PMID: 42035917. doi:10.1016/j.radonc.2026.111549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。